Anticancer therapies (one patient was on palbociclib and everolimus at different time points)	N = 202 (%)	Major bleeding		Non‐major bleeding		Venous thromboembolism		Arterial thrombosis
		N (%)	Cumulative incidence %, (95% CI)	N (%)	Cumulative incidence %, (95% CI)	N (%)	Cumulative incidence %, (95% CI)	N (%)	Cumulative incidence %, (95% CI)
EGFR and ALK inhibitors (osimertinib, alectinib)	43 (21.3%)	1/43 (2.3%)	2 (0.2–11)	1/43 (2.3%)	2 (0.2–11)	0		1/43 (2.3%)	2 (0.2–11)
BTK inhibitors (ibrutinib, acalbrutinib)	42 (20.8%)	4/42 (9.5%)	10 (3–21)	6/42 (14.3%)	14 (6–27)	0		0
Cyclin‐dependent kinase inhibitor (palbociclib)	42 (20.8%)	2/42 (4.8%)	5 (1–14)	3/42 (7.1%)	7 (2–18)	0		0
VEGF inhibitors (sunitinib, cabozantinib)	28 (13.9%)	2/28 (7.1%)	7 (1–21)	1/28 (3.6%)	4 (0.2–16)	2/28 (7.1%)	7 (1–21)	0
BCR‐ABL inhibitors (imatinib, nilotinib)	22 (10.9%)	0		0		0		1/22 (4.6%)	5 (0.3–19)
mTOR inhibitor (everolimus)	18 (8.9%)	0		1/18 (5.6%)	6 (0.3–23)	0		0
HER2 inhibitors (lapatinib)	4 (2.0%)	0		0		0		0
BRAF inhibitors (dabrafenib, vemurafenib)	4 (2.0%)	0		0		1/4 (25%)	25 (0.3–71)	0